On November 14, 2025, Cocrystal Pharma, Inc. (COCP) announced financial results for the third quarter of 2025 and provided a business update. The company has received IND clearance from the U.S. FDA to evaluate CDI-988 as both a norovirus preventive and treatment. We anticipate the company initiate a Phase 1b norovirus challenge study in the first quarter of 2026. In October 2025, Cocrystal was awarded a Small Business Innovation Research (SBIR) Phase I award from the U.S. National Institutes of Health (NIH) National Institute of Allergy and Infectious Diseases (NIAID). The approximately $500,000 award will support the development of a novel, oral, broad-spectrum antiviral candidate for the treatment of influenza A and B infections. Cocrystal recently completed a private placement with Directors and Management of the company for $1.03 million with an additional $1.8 million possible upon the exercise in full of warrants.
